Article
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.
The oncologist - 10 Mar 2025
Weber Jeffrey, Haque Waqas, Markovic Svetomir N, Salama April K S, Mehmi Inderjit, Sullivan Ryan J, Najjar Yana G, van Akkooi Alexander C J, Menzies Alexander M, Long Georgina V, Taylor Amelia M, Haanen John, Zijlker Lisanne P, Davis Keith L, Karanth Siddharth, Norton Deborah, Connolly Lucy
Abstract excerpt
BACKGROUND: In BRAF-mutated high-risk melanoma, targeted therapy (BRAF/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on differing action mechanisms of BRAF/MEK inhibitors and CPI immunotherapies, there is interest in evaluating the activity of 2L adjuvant targeted therapy in decreasing the risk of subsequent recurrence after repeat...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.